Perrigo acquisition could threaten Mylan's investment grade

April 10, 2015 8:03 PM

68 0

NEW YORK, April 10 (IFR) - Drugmaker Mylan is at risk of dropping back into junk territory if it doesn't strike a perfect balance between bond and equity to finance its proposed US$30bn acquisition of healthcare supplier Perrigo, analysts warned.

The Baa3/BBB- pharma has offered to buy Perrigo for US$205 a share in transaction valued at US$30bn, including assumed debt, and it may need to raise up to US$9bn to complete the acquisition.

Read more

To category page